The filing confirms SV Life Sciences as a significant pre-IPO holder with ~2.8M as-converted shares. Monitor for any subsequent Form 4 filings that would indicate selling post-IPO lockup expiration, which could signal insider sentiment.
Price Chart
Executive Summary
SV Life Sciences Fund VI, L.P. and affiliated entities filed a Form 3 initial statement of beneficial ownership for TRex Bio, Inc. (TRXB), disclosing aggregate beneficial ownership of approximately 2.8 million shares of common stock on an as-converted basis, held through preferred stock and direct common stock positions. The filing is a routine insider ownership disclosure triggered by the reporting persons becoming 10% beneficial owners, likely in connection with TRex Bio's IPO.
Key Facts
- SV Life Sciences Fund VI, L.P. and affiliates filed Form 3 for TRex Bio, Inc. (TRXB) on 2026-10-08.
- The reporting persons hold 125,086 shares of common stock directly via SV Life Sciences Fund VI, L.P. and 4,282 shares via SV Life Sciences Fund VI Strategic Partners, L.P.
- Preferred stock holdings: 1,574,074 shares of Series A Preferred and 475,411 shares of Series B Preferred held by SV Fund VI; 53,892 shares of Series A Preferred and 16,277 shares of Series B Preferred held by SV Strategic Partners VI; 669,939 shares of Series B Preferred held by SV Trex Coinvestment, L.P.
- Preferred stock converts to common stock at a ratio of 3.8649:1 upon closing of the issuer's initial public offering, for no additional consideration.
- Total as-converted common stock ownership is approximately 2.8 million shares (calculated from preferred shares at 3.8649:1 plus direct common shares).
- The filing is an initial statement of beneficial ownership, not a transaction.
Financial Impact
No financial impact from the filing itself; it discloses existing ownership positions.
Risk Factors
- Potential insider selling post-IPO lockup expiration could pressure stock price.
- Concentration of ownership in a single venture fund may lead to future dilution if the fund participates in follow-on offerings.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001829126-26-010932 |
| Document: 0001829126-26-010932-index.html | 0001829126-26-010932 |
| Document: 0001829126-26-010932.txt | 0001829126-26-010932 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.87 (−6.28%) |
Oct 16, 2026 10d ago | SC 13D | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.87 (−6.28%) |
Oct 16, 2026 10d ago | SC 13D | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.87 (−1.00%) |
Oct 15, 2026 11d ago | Insider Cluster | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.87 (−1.00%) |
Oct 15, 2026 11d ago | SC 13G | $14.16 $14.01 | ▼ −1.06% | ▲ +0.05% | $13.87 (−2.05%) |
Oct 13, 2026 13d ago | Press Release | $13.50 $14.16 | ▲ +4.89% | ▲ +4.60% | $13.87 (+2.74%) |
Oct 9, 2026 17d ago | 424B4 | $14.03 $13.60 | ▼ −3.06% | ▼ −3.05% | $13.87 (−1.14%) |
Oct 9, 2026 18d ago | EFFECT | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.87 (−0.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers